These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 32160474)

  • 1. Synthetic Immunogenic Cell Death Mediated by Intracellular Delivery of STING Agonist Nanoshells Enhances Anticancer Chemo-immunotherapy.
    Chattopadhyay S; Liu YH; Fang ZS; Lin CL; Lin JC; Yao BY; Hu CJ
    Nano Lett; 2020 Apr; 20(4):2246-2256. PubMed ID: 32160474
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma.
    Wang-Bishop L; Wehbe M; Shae D; James J; Hacker BC; Garland K; Chistov PP; Rafat M; Balko JM; Wilson JT
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically Edited Cascade Nanozymes for Cancer Immunotherapy.
    Zhang J; Pan Y; Liu L; Xu Y; Zhao C; Liu W; Rao L
    ACS Nano; 2024 May; 18(19):12295-12310. PubMed ID: 38695532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicines for an Enhanced Immunogenic Cell Death-Based
    Zhao C; Wang C; Shan W; Wang Z; Chen X; Deng H
    Acc Chem Res; 2024 Mar; 57(6):905-918. PubMed ID: 38417027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Self-Delivery Nanobooster to Enhance Immunogenic Cell Death for Cancer Chemoimmunotherapy.
    Yan C; Zhao Y; Liu X; Jiang Y; Li Q; Yang L; Li X; Luo K
    ACS Appl Mater Interfaces; 2024 Jul; 16(26):33169-33181. PubMed ID: 38915234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapy.
    Marloye M; Lawler SE; Berger G
    Pharm Pat Anal; 2019 Jul; 8(4):87-90. PubMed ID: 31354104
    [No Abstract]   [Full Text] [Related]  

  • 7. Spatiotemporal release of non-nucleotide STING agonist and AKT inhibitor from implantable 3D-printed scaffold for amplified cancer immunotherapy.
    Wang H; Liu Z; Fang Y; Luo X; Zheng C; Xu Y; Zhou X; Yuan Q; Lv S; Ma L; Lao YH; Tao Y; Li M
    Biomaterials; 2024 Dec; 311():122645. PubMed ID: 38850717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity.
    Wang Z; Chen J; Hu J; Zhang H; Xu F; He W; Wang X; Li M; Lu W; Zeng G; Zhou P; Huang P; Chen S; Li W; Xia LP; Xia X
    J Clin Invest; 2019 Aug; 129(11):4850-4862. PubMed ID: 31408442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular matrix-degrading STING nanoagonists for mild NIR-II photothermal-augmented chemodynamic-immunotherapy.
    Zhan M; Yu X; Zhao W; Peng Y; Peng S; Li J; Lu L
    J Nanobiotechnology; 2022 Jan; 20(1):23. PubMed ID: 34991618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymeric STING Pro-agonists for Tumor-Specific Sonodynamic Immunotherapy.
    Yu J; He S; Zhang C; Xu C; Huang J; Xu M; Pu K
    Angew Chem Int Ed Engl; 2023 Aug; 62(32):e202307272. PubMed ID: 37312610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered Nanovaccine Targeting Clec9a
    Gou S; Liu W; Wang S; Chen G; Chen Z; Qiu L; Zhou X; Wu Y; Qi Y; Gao Y
    Nano Lett; 2021 Dec; 21(23):9939-9950. PubMed ID: 34779631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ATP-Responsive Smart Hydrogel Releasing Immune Adjuvant Synchronized with Repeated Chemotherapy or Radiotherapy to Boost Antitumor Immunity.
    Sun L; Shen F; Tian L; Tao H; Xiong Z; Xu J; Liu Z
    Adv Mater; 2021 May; 33(18):e2007910. PubMed ID: 33788339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Co-delivery of Phagocytosis Checkpoint Silencer and Stimulator of Interferon Genes Agonist for Synergetic Cancer Immunotherapy.
    Lu ZD; Chen YF; Shen S; Xu CF; Wang J
    ACS Appl Mater Interfaces; 2021 Jun; 13(25):29424-29438. PubMed ID: 34129318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLR9 and STING agonists synergistically induce innate and adaptive type-II IFN.
    Temizoz B; Kuroda E; Ohata K; Jounai N; Ozasa K; Kobiyama K; Aoshi T; Ishii KJ
    Eur J Immunol; 2015 Apr; 45(4):1159-69. PubMed ID: 25529558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy.
    Yang S; Sun IC; Hwang HS; Shim MK; Yoon HY; Kim K
    J Mater Chem B; 2021 May; 9(19):3983-4001. PubMed ID: 33909000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale for stimulator of interferon genes-targeted cancer immunotherapy.
    Rivera Vargas T; Benoit-Lizon I; Apetoh L
    Eur J Cancer; 2017 Apr; 75():86-97. PubMed ID: 28219022
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Ultrasound-Triggered STING Pathway Nanoagonist for Enhanced Chemotherapy-Induced Immunogenic Cell Death.
    Tian Y; Tian H; Li B; Feng C; Dai Y
    Small; 2024 Jun; 20(26):e2309850. PubMed ID: 38225710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy.
    Duan X; Chan C; Lin W
    Angew Chem Int Ed Engl; 2019 Jan; 58(3):670-680. PubMed ID: 30016571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Agonists and inhibitors of the STING pathway: Potential agents for immunotherapy.
    Wu JJ; Zhao L; Hu HG; Li WH; Li YM
    Med Res Rev; 2020 May; 40(3):1117-1141. PubMed ID: 31793026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Redox-Activated Porphyrin-Based Liposome Remote-Loaded with Indoleamine 2,3-Dioxygenase (IDO) Inhibitor for Synergistic Photoimmunotherapy through Induction of Immunogenic Cell Death and Blockage of IDO Pathway.
    Liu D; Chen B; Mo Y; Wang Z; Qi T; Zhang Q; Wang Y
    Nano Lett; 2019 Oct; 19(10):6964-6976. PubMed ID: 31518149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.